

FOR IMMEDIATE RELEASE

Guanine Named Biological Measurement Software of the Year by Pharma Tech Outlook

Quantitative measurement of low-abundance nucleic acids, proteins, metabolites, cells and pathogens using proprietary software and patented electrochemical reporters

RENSELAER, NY and MONTREAL, QC — October 5, 2026 — Guanine Inc. has been named Biological Measurement Software of the Year by Pharma Tech Outlook, recognizing the company's approach to programmable biological measurement.

Guanine's proprietary software works exclusively with the company's patented stackable, reversible electrochemical redox reporters. Together, the software and reporter architecture convert biological interactions into programmable electrical signals that can be generated, encoded, stabilized and quantitatively analyzed using compact readers.

The platform is designed to measure multiple biological targets—including nucleic acids, proteins, metabolites, cells and pathogens—from a single sample. Guanine is being developed for quantitative, multi-analyte measurement, including low-abundance targets and biological changes over time.

Applications for Pharmaceutical Development

For pharmaceutical companies, the same measurement architecture could support multiple stages of drug development and patient treatment:

- **Clinical trials:** Quantitative multi-analyte testing at clinical sites and potentially in distributed or field settings, enabling biological measurements closer to the patient and reducing dependence on centralized laboratories.
- **Companion diagnostics (CDx):** Measurement of multiple biomarkers for patient selection, stratification and treatment response using a common measurement architecture.
- **Therapeutic drug monitoring (TDM):** Quantitative measurement of drugs, metabolites and biological-response markers, potentially including repeated measurements to characterize changes over time.

“Advanced tests and AI-driven biology require far more biological information—measured faster, more frequently, across more analytes and in more places,” said Neil Gordon, Founder and President of Guanine Inc. “Guanine is developing a common programmable electrical signal

layer designed to scale biological information without scaling instrument complexity. Programmability can reduce the trade-offs among multiplexing, sensitivity, time-resolved and distributed measurement without requiring a different measurement platform for every application.”

Guanine is developing the technology as an OEM measurement architecture, enabling partners to build suites of advanced assays on a common platform for pharmaceutical development, diagnostics and other biological measurement applications.

About Guanine Inc.

Guanine Inc. is developing a programmable architecture designed to measure biological information across analytes, across time and across applications—from advanced healthcare and precision medicine assays to industrial, environmental and biodefense measurement. AI and advanced analytics require more biological data, and Guanine is building the measurement architecture to generate it using cost-effective distributed readers. Guanine was incubated at Mount Sinai's Elementa Labs, including product-market validation of its sepsis strategy with approximately 20 clinical specialists. Its predecessor company was spun out from NASA's Ames Research Center. For more information, visit www.guanineinc.com.

Media & Business Inquiries

info@guanineinc.com

www.guanineinc.com

###